Cargando…
Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China
PURPOSE: Poly (ADP-ribose) polymerase (PARP) inhibitor, is a milestone in treatment of ovarian cancer. However, there is no real world study from China regarding the clinical outcome of the taking PARP inhibitor (PARPi), Olaparib(Lynparza™). The goal of this research is to evaluate the side effects...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882236/ https://www.ncbi.nlm.nih.gov/pubmed/31775908 http://dx.doi.org/10.1186/s13048-019-0594-1 |